HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gavestinel produces no benefit for stroke patients, study finds.

Abstract
There was only problem, it didn't work. The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant. The outcome has dimmed the optimism of hospitalists that rapid treatment would dramatically improve patient outcomes.
Authors
JournalClinical resource management (Clin Resour Manag) Vol. 2 Issue 11 Pg. 173-5, 161 (Nov 2001) United States
PMID11727452 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • 3-(2-((phenylamino)carbonyl)ethenyl)-4,6-dichloroindole-2-carboxylic acid
  • Indoles
  • Neuroprotective Agents
Topics
  • Aged
  • Aged, 80 and over
  • Clinical Trials, Phase III as Topic
  • Female
  • Humans
  • Indoles (therapeutic use)
  • Male
  • Middle Aged
  • Neuroprotective Agents (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Stroke (drug therapy)
  • Treatment Outcome
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: